Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

"We look forward to having this important discussion around stewardship and patients that would benefit from oral sulopenem with the FDA and its advisors at the Advisory Committee in September," said Corey Fishman, Chief Executive Officer. About Iterum Therapeutics plc This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the topics that will be cove ...